Analyst Consensus ?
ConsensusBuy24 ratings
Bullish2083.3%
Neutral416.7%
Bearish00.0%
BioNTech SE · BNTX · FY2026 Q2 · Calendar Q3 2026
BioNTech pivots toward oncology as vaccine demand weakens
BioNTech’s oncology pipeline and partnerships are central to its effort to offset falling COVID-19 vaccine revenue. The case depends on late-stage trial progress and execution as guidance has been reduced.
Reported Before market openNASDAQHealthcare
$21.83B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-3.70
Consensus $-2.40
EPS surprise
-54.3%
Reported versus consensus
Reported revenue
$120.6M
Consensus $180.2M
Revenue surprise
-33.1%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.0%
Event window
SPY move
+1.8%
Same window
Abnormal move
-2.8%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
+11.6%
Up to 20 sessions
BNTXSPY benchmark
Ask FN2 about BNTX FY2026 Q2
Transcript, numbers and history already loaded
Why did BNTX fall 1.0% after missing EPS estimates in FY2026 Q2?What changed in BNTX's guidance and outlook in FY2026 Q2?Give me the bull and bear case for BNTX after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management emphasized a tumor-focused, multiproduct oncology strategy, appointed Guido Oelkers as CEO, and outlined multiple Phase III programs. It also cited continued pressure on vaccine revenue and milestone timing as reasons for lower full-year revenue expectations.
Guidance delta
Management lowered full-year 2026 revenue guidance to €1.6–1.9 billion, citing reduced COVID-19 vaccine demand and delayed milestone payments.
Key takeaways
- Oncology development is the strategic focus, with pumitamig, gotistobart, LCD and T-Pam among the late-stage programs discussed.
- Management described several Phase III trials and anticipated further clinical milestones.
- Lower COVID-19 vaccine revenue and delayed milestones weighed on the outlook.
- The transcript analysis cited cash reserves and partnerships as support for continued research and development.
Management priorities
- Advance Phase III programs for pumitamig across multiple cancer types.
- Progress the gotistobart, LCD, BNT113 and T-Pam clinical programs.
- Continue development of mRNA cancer vaccine programs and partnered assets.
- Scale the business under new CEO Guido Oelkers.
Follow BNTX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$86.92Current
$81Low
$151.97Average
$359High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 4, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Canaccord Genuity | Buy | Buy | Maintain | Oct 14, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 7, 2026 |
| BMO Capital | Market Perform | Outperform | Downgrade | Sep 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 5, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 5, 2026 |
| UBS | Buy | Neutral | Upgrade | May 27, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 6, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Apr 27, 2026 |
| TD Cowen | Hold | Hold | Maintain | Mar 11, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 10, 2026 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 16, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 23, 2025 |
| B of A Securities | Buy | Buy | Maintain | Aug 5, 2025 |
| Truist Securities | Buy | Buy | Maintain | Jun 3, 2025 |
| HSBC | Buy | Buy | Maintain | Oct 7, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Sep 19, 2024 |
| HC Wainwright& Co. | Buy | Buy | Maintain | Jan 23, 2024 |
| Redburn Partners | Buy | Neutral | Upgrade | May 17, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jul 29, 2022 |
| Bryan Garnier | Buy | Neutral | Upgrade | Aug 11, 2021 |
| H.C. Wainwright | Neutral | Neutral | Maintain | Apr 13, 2020 |
| Wolfe Research | Outperform | Outperform | Maintain | Nov 5, 2019 |
| Berenberg | Buy | Buy | Maintain | Nov 4, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 4, 2019 |
Named analyst price targets
Upside is calculated against the persisted current price $86.92. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Canaccord Genuity | Analyst unavailable | $132 | $89.01 | +51.9% | Oct 14, 2026 |
| Morgan Stanley | Terence Flynn | $114 | $95.63 | +31.2% | Oct 7, 2026 |
| Berenberg Bank | Analyst unavailable | $140 | $96.69 | +61.1% | Sep 16, 2026 |
| BMO Capital | Evan David Seigerman | $105 | $103.76 | +20.8% | Sep 8, 2026 |
| Canaccord Genuity | Analyst unavailable | $136 | $102.08 | +56.5% | Aug 31, 2026 |
| Canaccord Genuity | Analyst unavailable | $142 | $91.35 | +63.4% | Aug 5, 2026 |
| Morgan Stanley | Analyst unavailable | $119 | $94.29 | +36.9% | Jul 8, 2026 |
| UBS | Analyst unavailable | $135 | $92.25 | +55.3% | May 27, 2026 |
| Bernstein | Analyst unavailable | $96 | $90.93 | +10.4% | May 21, 2026 |
| Canaccord Genuity | Analyst unavailable | $158 | $95.5 | +81.8% | May 6, 2026 |
| Morgan Stanley | Terence Flynn | $126 | $93.38 | +45.0% | Apr 10, 2026 |
| BMO Capital | Evan David Seigerman | $128 | $90.52 | +47.3% | Mar 11, 2026 |
| Jefferies | Akash Tewari | $138 | $83.89 | +58.8% | Mar 10, 2026 |
| Truist Financial | Asthika Goonewardene | $155 | $83.89 | +78.3% | Mar 10, 2026 |
| Morgan Stanley | Analyst unavailable | $128 | $83.89 | +47.3% | Mar 10, 2026 |
| Leerink Partners | Analyst unavailable | $113 | $113.75 | +30.0% | Feb 2, 2026 |
| Goldman Sachs | Analyst unavailable | $142 | $106.07 | +63.4% | Jan 16, 2026 |
| Berenberg Bank | Harry Gillis | $155 | $95.68 | +78.3% | Dec 11, 2025 |
| H.C. Wainwright | Raghuram Selvaraju | $140 | $96.91 | +61.1% | Dec 11, 2025 |
| Morgan Stanley | Analyst unavailable | $134 | $103.96 | +54.2% | Nov 3, 2025 |
| Morgan Stanley | Terence Flynn | $131 | $104.48 | +50.7% | Oct 10, 2025 |
| Wells Fargo | Mohit Bansal | $150 | $111.07 | +72.6% | Aug 5, 2025 |
| Morgan Stanley | Terence Flynn | $133 | $112.26 | +53.0% | Jul 10, 2025 |
| Leerink Partners | Daina Graybosch | $112 | $113.1 | +28.9% | Jun 2, 2025 |
| Goldman Sachs | Asad Haider | $110 | $98.45 | +26.6% | May 29, 2025 |
| H.C. Wainwright | Robert Burns | $134 | $97.27 | +54.2% | May 14, 2025 |
| H.C. Wainwright | Analyst unavailable | $145 | $90.29 | +66.8% | Apr 1, 2025 |
| Evercore ISI | Cory Kasimov | $125 | $80.8 | +43.8% | Nov 19, 2024 |
| Leerink Partners | Daina Graybosch | $121 | $80.8 | +39.2% | Nov 13, 2024 |
| Goldman Sachs | Chris Shibutani | $137 | $110.66 | +57.6% | Nov 8, 2024 |
| BMO Capital | Etzer Darout | $126 | $108.97 | +45.0% | Nov 4, 2024 |
| Morgan Stanley | Terence Flynn | $145 | $113.05 | +66.8% | Sep 23, 2024 |
| Jefferies | Akash Tewari | $150 | $123.97 | +72.6% | Sep 17, 2024 |
| Bank of America Securities | Tazeen Ahmad | $150 | $123.4 | +72.6% | Sep 16, 2024 |
| Jefferies | Akash Tewari | $96 | $105 | +10.4% | Sep 13, 2024 |
| Deutsche Bank | Emmanuel Papadakis | $95 | $79.5 | +9.3% | Aug 6, 2024 |
| Morgan Stanley | Terence Flynn | $93 | $78.36 | +7.0% | Aug 5, 2024 |
| HSBC | Yifeng Liu | $101 | $82.01 | +16.2% | Aug 2, 2024 |
| H.C. Wainwright | Raghuram Selvaraju | $113 | $82.52 | +30.0% | Jun 26, 2024 |
| Evercore ISI | Cory Kasimov | $100 | $92.72 | +15.0% | May 13, 2024 |
| BMO Capital | Etzer Darout | $122 | $91.53 | +40.4% | May 7, 2024 |
| HSBC | Yifeng Liu | $90 | $91.83 | +3.5% | Mar 22, 2024 |
| Canaccord Genuity | William Maughan | $171 | $91.99 | +96.7% | Mar 21, 2024 |
| BMO Capital | Etzer Darout | $123 | $91.99 | +41.5% | Mar 21, 2024 |
| Goldman Sachs | Chris Shibutani | $91 | $91.99 | +4.7% | Mar 21, 2024 |
| Goldman Sachs | Analyst unavailable | $156 | $143.41 | +79.5% | Jan 31, 2023 |
| Leerink Partners | Mani Foroohar | $81 | $169.47 | -6.8% | Dec 2, 2022 |
| UBS | Andrew Ang | $168 | $159.8 | +93.3% | May 17, 2022 |
| Morgan Stanley | Matthew Harrison | $195 | $140.32 | +124.3% | May 10, 2022 |
| H.C. Wainwright | Robert Burns | $298 | $175.29 | +242.8% | Apr 16, 2022 |
| Canaccord Genuity | Arlinda Lee | $300 | $170.26 | +245.1% | Apr 10, 2022 |
| UBS | Eliana Merle | $170 | $147.5 | +95.6% | Jan 21, 2022 |
| Kempen & Co | Suzanne van Voorthuizen | $350 | $259.7 | +302.7% | Dec 22, 2021 |
| Leerink Partners | Daina Graybosch | $253 | $284.21 | +191.1% | Dec 9, 2021 |
| Bryan Garnier & Co Ltd | Olga Smolentseva | $359 | $248.9 | +313.0% | Oct 4, 2021 |
Track every rating change on BNTX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors.…
Historical context
All BNTX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | +24.3% | +3.2% | Philips Q3: Orders Rise and Margin Expands; Full-Year Outlook Unchanged |
| PFE Pfizer Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.0% | Pfizer raises 2026 guidance as launched portfolio growth offsets longer-term pressures |
| TEVA Teva Pharmaceutical Industries Limited | FY2026 Q3 · Calendar Q4 2026 | — | +3.3% | Teva’s innovative portfolio grows as revenue guidance rises |
| FMS Fresenius Medical Care AG & Co. KGaA | FY2026 Q3 · Calendar Q4 2026 | — | -3.6% | Fresenius Medical Care cuts 2026 outlook as cost and reimbursement pressure persist |
| RVTY Revvity, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +10.8% | Revvity Raises FY2026 Outlook After 7% Q3 Organic Growth |
| WAT Waters Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +3.8% | Waters Raises FY2026 Revenue Outlook as Organic Growth Accelerates |
Latest beats and misses
Who reports nextBeat on EPS
- APTVFY2026 Q3 · November 3, 2026+6.8% EPS-6.5% move
- PHGFY2026 Q3 · November 3, 2026+24.3% EPS+3.2% move
- FANGFY2026 Q3 · November 2, 2026+2.4% EPS-3.7% move
- RRXFY2026 Q3 · November 3, 2026+41.1% EPS+11.8% move
- UDRFY2026 Q3 · November 2, 2026+340.8% EPS+0.1% move
- VNOMFY2026 Q3 · November 2, 2026+3.9% EPS-2.6% move
Get the BNTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-05T18:10:20.125836+00:00
- FN2 earnings calendar · 2026-09-09T01:23:14.388487+00:00
- Polygon adjusted daily market bars · 2026-11-04T02:00:43.775803+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T02:00:43.773021+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.